The estimated Net Worth of Joseph Vittiglio is at least $2.61 Millón dollars as of 5 February 2024. Mr. Vittiglio owns over 5,217 units of AMAG Pharmaceuticals stock worth over $1,119,575 and over the last 12 years he sold AMAG stock worth over $77,089. In addition, he makes $1,411,860 as Executive Vice President, General Counsel, Corporate Secretary y Chief Business Officer at AMAG Pharmaceuticals.
Joseph has made over 7 trades of the AMAG Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 5,217 units of AMAG stock worth $4,695 on 5 February 2024.
The largest trade he's ever made was selling 5,430 units of AMAG Pharmaceuticals stock on 29 January 2014 worth over $8,905. On average, Joseph trades about 702 units every 149 days since 2013. As of 5 February 2024 he still owns at least 44,783 units of AMAG Pharmaceuticals stock.
You can see the complete history of Mr. Vittiglio stock trades at the bottom of the page.
Joseph D. Vittiglio J.D. serves as Executive Vice President, General Counsel, Corporate Secretary, Chief Business Officer of the Company. He is our Executive Vice President, Chief Business Officer and General Counsel & Corporate Secretary, joined us in August 2015 as our Senior Vice President, Legal Affairs, General Counsel and Secretary. Prior to joining us, Mr. Vittiglio served from March 2015 to August 2015 as Vice President of Legal Affairs and a member of the Management Committee at Flexion Therapeutics, Inc. ("Flexion"), a public pharmaceutical company. Prior to Flexion, Mr. Vittiglio was the General Counsel and Secretary of AVEO Pharmaceuticals, Inc., a public biopharmaceutical company, from 2007 to March 2015. From 2005 to 2007, he served as Director of Corporate Legal Affairs at Oscient Pharmaceuticals Corporation ("Oscient"), a public pharmaceutical company. Prior to Oscient, Mr. Vittiglio was a senior corporate associate from 1998 to 2005 at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC. Mr. Vittiglio holds a B.A. in International Relations from Tufts University and a J.D. from Northeastern University School of Law.
As the Executive Vice President, General Counsel, Corporate Secretary y Chief Business Officer of AMAG Pharmaceuticals, the total compensation of Joseph Vittiglio at AMAG Pharmaceuticals is $1,411,860. There are no executives at AMAG Pharmaceuticals getting paid more.
Joseph Vittiglio is 49, he's been the Executive Vice President, General Counsel, Corporate Secretary y Chief Business Officer of AMAG Pharmaceuticals since 2020. There are 8 older and 4 younger executives at AMAG Pharmaceuticals. The oldest executive at AMAG Pharmaceuticals, Inc. is Davey Scoon, 73, who is the Independent Director.
Joseph's mailing address filed with the SEC is C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE, MA, 02145.
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C.... y Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: